Page last updated: 2024-08-23

daunorubicin and wp 744

daunorubicin has been researched along with wp 744 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aggarwal, BB; Ashikawa, K; Fokt, I; Priebe, W; Shishodia, S1
Baer, MR; Bernacki, RJ; Brooks, TA; Bundy, BN; Ford, LA; Minderman, H; O'Loughlin, KL; Priebe, W; Vredenburg, MR1

Other Studies

2 other study(ies) available for daunorubicin and wp 744

ArticleYear
Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues.
    Biochemical pharmacology, 2004, Jan-15, Volume: 67, Issue:2

    Topics: Anthracyclines; Antibiotics, Antineoplastic; Daunorubicin; DNA, Neoplasm; Doxorubicin; Humans; I-kappa B Proteins; Jurkat Cells; NF-kappa B; NF-KappaB Inhibitor alpha; Transcription Factors; Tumor Cells, Cultured

2004
The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.
    Investigational new drugs, 2007, Volume: 25, Issue:2

    Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Survival; Daunorubicin; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorescence; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins

2007